Aquestive therapeutics expands license and supply agreement with pharmanovia for libervant™ (diazepam) buccal film to additional global markets

Warren, n.j., march 29, 2023 (globe newswire) -- aquestive therapeutics, inc. (nasdaq:aqst), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today announced it has expanded its exclusive license and supply agreement with atnahs pharma uk limited (“pharmanovia”), a global pharmaceutical company that revitalizes, extends and expands the lifecycle of established medicines, for libervant™ (diazepam) buccal film to cover the rest of the world, excluding the united states, canada, and china. the original licensing agreement with pharmanovia announced in september 2022 covered the european union, united kingdom, sweden, switzerland, and norway, as well as countries in the middle east and north africa (mena).
AQST Ratings Summary
AQST Quant Ranking